HOME >> BIOLOGY >> NEWS
G6PD deficiency is associated with significant protection against severe, life-threatening malaria

A case-control study in two populations in Mali, West Africa has shown that glucose-6-phosphate dehydrogenase (G6PD) deficiency is associated with significant protection against severe, life-threatening malaria. Researchers from the US National Institute of Allergy and Infectious Diseases and the University of Bamako, Mali, led by Thomas E. Wellems, report the findings this week in the open access journal PLoS Medicine.

G6PD deficiency is also known as favism after the Italian word for broad beans (fava) which cause a classic reaction when eaten by people with G6PD deficiency. In males, who have only one X chromosome, mutations in the gene for G6PD on the X chromosome cause G6PD deficiency. Females who have mutations on both X chromosomes will also be deficient. G6PD is an important enzyme in red blood cells (erythrocytes), the host cells for Plasmodium falciparum, the parasite that causes the most severe form of malaria. G6PD deficiency is associated with protection against malaria, notably in Africa where one form of G6PD deficiency (G6PD A-) is widespread.

In the two populations of more than 3000 children studied in rural Mali where malaria is very frequent, G6PD deficiency in male and female children was associated with protection against severe, life-threatening malaria, but no effect was found in females who had just one abnormal gene. However, there was no significant difference in the numbers of parasites in the red blood cells of the various groups of children indicating that the deficiency does not work by stopping parasites from infecting the children. G6PD deficiency instead appears to mitigate disease processes set up by the parasitized cells in the bloodstream. The protection was confirmed by a combined analysis of these data and data from a previous study. Protection was most evident against cerebral malaria, the most frequent form of life-threatening malaria in these studies.

These results reignite the debate about t
'"/>

Contact: Andrew Hyde
press@plos.org
44-122-346-3330
Public Library of Science
12-Mar-2007


Page: 1 2

Related biology news :

1. Study suggests estrogen deficiency can lead to obesity-induced high blood pressure after menopause
2. Vitamin D deficiency widespread during pregnancy
3. The new form of trypanosomiasis discovered in India stems from a deficiency in apolipoproteinL-1
4. Poor athletic performance linked to vitamin deficiency
5. Dartmouth study contributes to research addressing malnutrition and iron deficiency
6. Heavy drinking can hasten the progression of the simian immunodeficiency virus disease
7. Study illuminates birth defects caused by copper deficiency
8. Study finds that nutritionally enhanced rice reduces iron deficiency
9. Enzyme deficiency may contribute to liver cancer, Mount Sinai research indicates
10. Gene for immune deficiency syndromes found
11. Rapid, new test develped for inherited immune deficiency

Post Your Comments:
(Date:7/13/2015)... OXFORD, Conn. , Jul. 13, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... it has filed provisional patent 62/188684 for ... NXT-ID achieves another new convenient and secure method ... expands new, innovative payment methods, introduced with its ...
(Date:7/9/2015)... July 9, 2015  Unchained Labs just can,t ... acquisition of Avid Nano. Avid Nano designs, develops ... systems.    Also today, Unchained Labs ... easiest to use protein sizing system. The pUNk ... protein,s hydrodynamic size, size distribution, aggregation population and ...
(Date:7/8/2015)... LAKES , N.J. and NEW YORK ... Company) and Guidepoint today announced BD ... start-up healthcare companies with free access to Guidepoint,s expert ... several start-ups that are developing cutting-edge technologies to improve ... a dedicated Guidepoint research manager, each start-up entrepreneur will ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
(Date:7/30/2015)... Ascendis Pharma A/S (Nasdaq: ASND ... TransCon technology to address significant unmet medical needs, ... Phase 2 study to evaluate the safety and ... treatment-naïve, pre-pubertal children with growth hormone deficiency, or ... the top-line results from our Phase 2 pediatric ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... advanced fluid applications and designed for continuous operation up to 1500 bar. The ... ensuring safety, efficiency, and preventing toxic contamination. , The Pony™ NS2006L homogenizer is ...
(Date:7/29/2015)... 29, 2015 US-Australian drug discovery company, Novogen ... it is committed to progressing its ground-breaking technology platforms ... and to ensure the Company delivers the best value ... Iain Ross , said the Company currently had an ... programs, discovery programs and academic partnerships and initiatives, and ...
(Date:7/29/2015)... FRANCISCO , July 29, 2015  AsureQuality ... mobile molecular testing for applications in food and ... hand-held, battery powered real-time PCR device, the Freedom4. ... farm right through to the supermarket shelf for ... This includes involvement in animal disease control and ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2
Cached News: